2. Signaling Pathways
  3. Immunology/Inflammation
  4. CD3
  5. CD3 Ligand

CD3 Ligand

CD3 Ligands (3):

Cat. No. Product Name Effect Purity
  • HY-P99910
    Eluvixtamab
    		Ligand
    Eluvixtamab (AMG-330) is a bispecific T-cell engager. Eluvixtamab binds to CD33 and CD3 on T cells, thereby promoting T cell-mediated cytotoxicity against CD33+ cells. Eluvixtamab can be used in the research of tumors such as relapsed/refractory acute myeloid leukemia.
  • HY-P99948
    Etevritamab
    		Ligand
    Etevritamab (AMG-596) is a bispecific T-cell engager targeting EGFRvIII and CD3. Etevritamab can simultaneously bind to the tumor-specific antigen EGFRvIII on glioblastoma multiforme and CD3 on T cells, thereby activating T-cell proliferation and secretion of cytotoxic substances to induce lysis of the bound tumor cells. Etevritamab can be used for the research of tumors such as glioblastoma multiforme.
  • HY-P991122
    Besufetamig
    		Ligand 99.98%
    Besufetamig is a bispecific antibody targeting programmed cell death 1 (PD-1) and CD3ε chain. Besufetamig modulates the activity of immune cells, exerting immunosuppressive and antineoplastic activities. Besufetamig is promising for research of cancers.